Results 51 to 60 of about 1,710 (123)

Impact of Elexacaftor-Tezacaftor-Ivacaftor on Quality of Life in Children With Cystic Fibrosis. [PDF]

Pediatr Pulmonol
Kümmerli S, Elviro CF, Regamey N, Mornand A, Faouzi M, Rochat I, Blanchon S.   +6 more
europepmc   +1 more source

Reply to Piehler et al.: Depression Symptoms in Patients with Cystic Fibrosis Fluctuate at Baseline and Improve with Elexacaftor/Tezacaftor/Ivacaftor Therapy. [PDF]

Am J Respir Crit Care Med
Duff AJA, Lee TWR.
europepmc   +1 more source

Piperine suppresses M1 phenotype and induces indoleamine 2,3-dioxygenase gene in LPS-stimulated murine macrophage cell line. [PDF]

BMC Res Notes
Gholijani N, Dehghan Z, Abolmaali SS, Talepoor AG, Kalantar K, Daryabor G.   +5 more
europepmc   +1 more source

Enantioselective radical chemistry: a bright future ahead. [PDF]

Beilstein J Org Chem
Renner AC, Thorat SS, Subramanian H, Sibi MP.   +3 more
europepmc   +1 more source

Assessment of efficacy and tolerability of elexacaftor-tezacaftor-ivacaftor in an observational cohort study of "aged" people with cystic fibrosis. [PDF]

Ther Adv Respir Dis
Blankenship S, Flueckiger BV, Caleb G, Bailey J, Baker E, Garcia B, Krick S.   +6 more
europepmc   +1 more source

Impact of Elexacaftor-Tezacaftor-Ivacaftor on Gastrointestinal Symptoms, Intestinal Ultrasound, and Pancreatic Stiffness in Cystic Fibrosis. [PDF]

Clin Transl Gastroenterol
Fraquelli M, Piagnani A, Corti F, Lanfranchi C, Casazza G, Colombo C.   +5 more
europepmc   +1 more source

Home-based sleep monitoring using a novel non-contact, radar-based biomotion sensor in adults with cystic fibrosis treated with elexacaftor/tezacaftor/ivacaftor. [PDF]

Sleep Breath
Dietz-Terjung S, Straßburg S, Schöbel C, Schulte T, Dietz P, Gahbiche FE, Ortiz J, Taube C, Weinreich G, Sutharsan S, Welsner M.   +10 more
europepmc   +1 more source

Effects of cAMP and CFTR modulation on apical fluid pH in human airway Calu-3 cells. [PDF]

Physiol Rep
Nguyen JP, Milad N, Hirota JA.
europepmc   +1 more source

Ivacaftor-tezacaftor-elexacaftor, tezacaftor-ivacaftor and lumacaftor-ivacaftor for treating cystic fibrosis: a systematic review and economic evaluation.

Health Technol Assess
Edwards SJ, Farrar BG, Ennis K, Downes N, Wakefield V, Mackenzie I, Walters A, Jhita T.   +7 more
europepmc   +1 more source

Phosphatidylserine liposomes for <i>Mycobacterium abscessus</i> infections management in people with cystic fibrosis non-eligible for CFTR modulators. [PDF]

Front Immunol
Olimpieri T, Poerio N, Saliu F, Lorè NI, Ciciriello F, Ponsecchi G, Alghisi F, Cirillo DM, D'Andrea MM, Fraziano M.   +9 more
europepmc   +1 more source